NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited. [Read more…]
World Organoid Research Day+ 2024
Attracts Leading Researchers & Technologies
Ticket sales help fund organoid research.
November 9th 2024, HERTFORDSHIRE, UNITED KINGDOM
After the success of this year’s 2023 event, World Organoid Research Day+ will be in person in Cambridge, UK, in 2024.
How 3D Printing with Stem Cells will Alter the Future of Medicine
Without question, 3D printing is one of the most transformative technologies of the 21st century, impacting diverse fields that include medicine, science, technology, manufacturing, military defense, and more. Among its exciting and varied applications, combining 3D printing technologies with stem cells is one of the most exciting.
For this reason, this article explores critical advances in 3D printing and how this technology is creating positive opportunities for stem cell companies and investors.
Avid Bioservices Completes Construction of World-Class Cell and Gene Therapy Development & Manufacturing Facility
Newly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024
Completion of CGT Facility Brings Company’s Total Revenue Generating Capacity to up to Approximately $400 Million Annually
- « Previous Page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- …
- 339
- Next Page »